The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease

Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease

(2023) Xing Ying et al.   Frontiers in Microbiology

Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease

(2023) Dimitrios D Raptis et al.   Therapeutics and Clinical Risk Management

Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy

(2023) Stergios A. Polyzos et al.   SEMINARS IN CANCER BIOLOGY

TNF in the liver: targeting a central player in inflammation

(2022) Gisa Tiegs et al.   Seminars in Immunopathology

Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease

(2022) Yamei Duan et al.   Frontiers in Immunology

Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world

(2022) Linda Henry et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Combination Therapies for Nonalcoholic Fatty Liver Disease

(2022) Evangelia S. Makri et al.   Journal of Personalized Medicine

Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: A randomized double-blind active-controlled trial

(2022) Muhammad Amjad Pervez et al.   COMPLEMENTARY THERAPIES IN MEDICINE

The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials

(2022) Dongmei Wang et al.   Frontiers in Pharmacology

Hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Disease Primers

Necroptosis, pyroptosis and apoptosis: an intricate game of cell death

(2021) Damien Bertheloot et al.   Cellular & Molecular Immunology

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial

(2021) Samer Gawrieh et al.   HEPATOLOGY

Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations

(2021) Stergios A. Polyzos et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease

(2021) Evangelia S. Makri et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Circulating tumor necrosis factor‐α levels in non‐alcoholic fatty liver disease: A systematic review and a meta‐analysis

(2021) Victoria Potoupni et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Co‑administration of obeticholic acid and simvastatin protects against high‑fat diet‑induced non‑alcoholic steatohepatitis in mice

(2021) Wen-Cong Li et al.   Experimental and Therapeutic Medicine

Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression

(2021) Tereza C. M. Fontes-Cal et al.   Frontiers in Immunology

Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents

(2021) Apostolis Papaefthymiou et al.   Journal of Crohns & Colitis

Tumor necrosis factor-α signaling in nonalcoholic steatohepatitis and targeted therapies

(2021) Sijia Lu et al.   Journal of Genetics and Genomics

Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model

(2021) Hu Li et al.   Frontiers in Pharmacology

Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

(2021) Ju Li et al.   Frontiers in Pharmacology

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

(2021) Rasoul Akbari et al.   BMC Pharmacology & Toxicology

Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns

(2020) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

(2020) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates

(2020) Aoyuan Cui et al.   DIABETES

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages

(2020) Sander Lefere et al.   JOURNAL OF HEPATOLOGY

Lytic cell death in metabolic liver disease

(2020) Jérémie Gautheron et al.   JOURNAL OF HEPATOLOGY

TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice

(2020) Franziska Wandrer et al.   Cell Death & Disease

Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

(2020) Austin Lin et al.   INFLAMMATORY BOWEL DISEASES

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

(2020) Divya P. Kumar et al.   Scientific Reports

Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice

(2020) Sena Bluemel et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?

(2020) Patricia Rada et al.   Cell Death & Disease

Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease

(2020) Evangelia Makri et al.   ARCHIVES OF MEDICAL RESEARCH

Acute Elevated Resistin Exacerbates Mitochondrial Damage and Aggravates Liver Steatosis Through AMPK/PGC-1α Signaling Pathway in Male NAFLD Mice

(2020) Fengyun Wen et al.   HORMONE AND METABOLIC RESEARCH

Even Short-Term Telmisartan Treatment Ameliorated Insulin Resistance But Had No Influence on Serum Adiponectin and Tumor Necrosis Factor-Alpha Levels in Hypertensive Patients with Metabolic Syndrome

(2019) Sinem Kiyici et al.   Metabolic Syndrome and Related Disorders

Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis

(2019) Naotaka Shimozato et al.   HEPATOLOGY RESEARCH

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH

(2019) Jonathan D. Roth et al.   Scientific Reports

Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients

(2019) Alessandro Federico et al.   Oxidative Medicine and Cellular Longevity

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways

(2019) Ying Luo et al.   Drug Design Development and Therapy

Tumor necrosis factor-α promotes hepatocellular carcinogenesis through the activation of hepatic progenitor cells

(2018) Yingying Jing et al.   CANCER LETTERS

Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids

(2018) Gabriela S. de Castro et al.   CLINICAL NUTRITION

Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD

(2018) Amir Hadi et al.   CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION

Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease

(2018) Kamolyut Lapumnuaypol et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Pharmacotherapy of type 2 diabetes: An update

(2018) Jagriti Upadhyay et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Triggering and resolution of inflammation in NASH

(2018) Susanne Schuster et al.   Nature Reviews Gastroenterology & Hepatology

Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis

(2018) Toshihiro Goto et al.   Scientific Reports

Rifaximin in nonalcoholic fatty liver disease

(2018) Ahmed Abdel-Razik et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Molecular pathways of nonalcoholic fatty liver disease development and progression

(2018) Fernando Bessone et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study

(2017) Jeremy F.L. Cobbold et al.   HEPATOLOGY RESEARCH

Pivotal Role of TNF-α in the Development and Progression of Nonalcoholic Fatty Liver Disease in a Murine Model

(2017) Satomi Kakino et al.   HORMONE AND METABOLIC RESEARCH

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

(2017) Mukul R. Jain et al.   LIVER INTERNATIONAL

A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients

(2016) Ahmed Abdel-Razik et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Emerging and future therapies for nonalcoholic steatohepatitis in adults

(2016) Gesthimani Mintziori et al.   EXPERT OPINION ON PHARMACOTHERAPY

Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease

(2016) Veeral Ajmera et al.   HEPATOLOGY

Adipokines in nonalcoholic fatty liver disease

(2016) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review

(2016) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

(2016)   Obesity Facts

Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease

(2015) Venkatanarayana Gangarapu et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders

(2015) Soo Lim et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease

(2015) Shweta Kapil et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma

(2015) Hamza Chettouh et al.   LIVER INTERNATIONAL

Synergistic effect of pro-inflammatory TNFα and IL-17 in periostin mediated collagen deposition: Potential role in liver fibrosis

(2015) Suneetha Amara et al.   MOLECULAR IMMUNOLOGY

Suppressor of cytokine signalling (SOCS) proteins as guardians of inflammatory responses critical for regulating insulin sensitivity

(2014) Sandra Galic et al.   BIOCHEMICAL JOURNAL

Pentoxifylline for the treatment of nonalcoholic fatty liver disease

(2014) Tao Zeng et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial

(2014) Arun J. Sanyal et al.   GASTROENTEROLOGY

Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis

(2014) Juan Du   WORLD JOURNAL OF GASTROENTEROLOGY

Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients

(2013) Luisa Costa et al.   CLINICAL RHEUMATOLOGY

Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice

(2013) Jean-Philippe Pradere et al.   HEPATOLOGY

Tumor Necrosis Factor-α Promotes Cholestasis-Induced Liver Fibrosis in the Mouse through Tissue Inhibitor of Metalloproteinase-1 Production in Hepatic Stellate Cells

(2013) Yosuke Osawa et al.   PLoS One

Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property

(2012) Hideyuki Hyogo et al.   DIGESTIVE AND LIVER DISEASE

How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease

(2012) Mariana V. Machado et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Hepatic Steatosis and Disease Activity in Subjects with Psoriatic Arthritis Receiving Tumor Necrosis Factor-  Blockers

(2012) M. N. D. Di MINNO et al.   JOURNAL OF RHEUMATOLOGY

Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats

(2012) Yoshihisa Okada et al.   LIVER INTERNATIONAL

Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development

(2011) Anna Alisi et al.   HEPATOLOGY

The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis

(2011) Suzanne E. Mahady et al.   JOURNAL OF HEPATOLOGY

Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients

(2011) Edith Koehler et al.   LIVER INTERNATIONAL

Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis

(2010) N. Alcorn et al.   ANNALS OF THE RHEUMATIC DISEASES

The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats

(2010) Su Liu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The Potential Adverse Role of Leptin Resistance in Nonalcoholic Fatty Liver Disease

(2010) Stergios A. Polyzos et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice

(2010) Giridhar Kanuri et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Adipocytokines in insulin resistance and non-alcoholic fatty liver disease: The two sides of the same coin

(2010) Stergios A. Polyzos et al.   MEDICAL HYPOTHESES

Systematic review and meta-analysis: Anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis

(2010) Cheryl Barnabe et al.   ARTHRITIS CARE & RESEARCH

Hepatoprotective effect of tumour necrosis factor   blockade in psoriatic arthritis: a cross-sectional study

(2009) M. Seitz et al.   ANNALS OF THE RHEUMATIC DISEASES

Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines

(2009) Stergios Polyzos et al.   CURRENT MOLECULAR MEDICINE

Highly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis

(2009) Naoki Tanaka et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

56 LONG-TERM EFFICACY OF ROSIGLITAZONE IN NONALCOHOLIC STEATOHEPATITIS (NASH): RESULTS OF THE EXTENSION PHASE OF THE FLIRT-2 TRIAL

(2009) V. Ratziu et al.   JOURNAL OF HEPATOLOGY

Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis

(2009) Maria Luisa Balmer et al.   LIVER INTERNATIONAL

Triglyceride Levels and Not Adipokine Concentrations Are Closely Related to Severity of Nonalcoholic Fatty Liver Disease in an Obesity Surgery Cohort

(2009) Sangeeta R. Kashyap et al.   Obesity

Adalimumab Could Suppress the Activity of Non Alcoholic Steatohepatitis (NASH)

(2008) C Schramm et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease

(2007) L. Spadaro et al.   DIGESTIVE AND LIVER DISEASE